Advertisement

Picture Fairtec GmbH We Optimise the ROI of Your Event 600x60px
Document › Details

Molecular Partners AG. (9/7/16). "Press Release: Molecular Partners to Present at the Morgan Stanley Global Healthcare Conference in New York". Zürich-Schlieren.

Organisations Organisation Molecular Partners AG (SIX: MOLN)
  Organisation 2 Morgan Stanley (Group)
Products Product Morgan Stanley Global Healthcare Conference 2016 New York
  Product 2 DARPin (Designed Ankyrin Repeat Protein)
Index term Index term Molecular Partners–Morgan Stanley: investor conference, 201609 supply service Molecular Partners at Morgan Stanley Global Healthcare Conference
Persons Person Zahnd, Christian (Molecular Partners 200708 CEO)
  Person 2 Emmenegger, Andreas (Molecular Partners 201603 CFO)
     


Molecular Partners AG (SIX: MOLN), a clinical-stage biopharmaceutical company that is developing a new, class of therapies known as DARPins, today announced that Dr. Christian Zahnd, CEO and Andreas Emmenegger, CFO of Molecular Partners will participate in a fireside chat at the Morgan Stanley Global Healthcare Conference on Monday, September 12, 2016 at 5:25 PM Eastern Time (11:25 PM CET).

The presentation will be available for viewing via live webcast and can be accessed on the day through this link. A replay of the webcast will be made available on the company’s website www.molecularpartners.com under the Investors section. The replay will be available for 180 days following the presentation.


About Molecular Partners AG

Molecular Partners AG is a clinical-stage biopharmaceutical company that is developing a new, class of therapies known as DARPins. DARPins are potent, specific, and versatile small-protein therapies, which have the potential to offer benefits over conventional monoclonal antibodies or other currently available protein therapeutics. The DARPin® technology has the potential to offer a multi-specific approach to treatment, which enables DARPins to target multiple pathways, or multiple epitopes on a single target to achieve substantial patient benefit. DARPins have the potential to advance modern medicine and significantly improve the treatment of serious diseases, including cancer and sight-threatening disorders.

Molecular Partners has four compounds in various stages of clinical and preclinical development and several more in the research stage, with a current focus on ophthalmology and oncology. The company has ongoing research and development partnerships with leading pharmaceutical companies, including Allergan and Janssen, and is backed by established biotech investors. For more information regarding Molecular Partners AG, go to: www.molecularpartners.com.


For further details, please contact:

Dr. Christian Zahnd, CEO
christian.zahnd@molecularpartners.com
Tel: +41 (0) 44 755 77 00

Andreas Emmenegger, CFO
andreas.emmenegger@molecularpartners.com
Tel: +41 (0) 44 755 77 00

Rolf Schläpfer
Hirzel.Neef.Schmid.Counselors
rolf.schlaepfer@konsulenten.ch
Tel: +41 (0) 43 344 42 42

S.A. Noon
Susan A. Noonan Communications, LLC
susan@sanoonan.com
Tel: +1 212 966 3650

   
Record changed: 2017-07-02

Advertisement

Picture Fairtec GmbH Worldwide Event Solutions 600x60px

More documents for Molecular Partners AG (SIX: MOLN)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture EBD Group Biotech Showcase 2018 BTS San Francisco January 600x60px




» top

Advertisements

Picture [iito] Twitter iitoLifeScience Life Sciences Mass Spec 120x120px Picture EBD Group Biotech Showcase 2018 BTS San Francisco January 120x180px Picture [LSE] Life-Sciences-Europe.com – The Business Web Portal 120x600px Banner Fairtec GmbH Solutions for Smarter Business Events Exhibitions 120x120px Picture [iito] Twitter iitoLifeScience Life Sciences Mass Spec 120x120px Picture EBD Group Biotech Showcase 2018 BTS San Francisco January 120x180px